Kidney Cancer Research Consortium May Advance Progress in the Field

Commentary
Video
Conference|Kidney Cancer Research Summit (KCRS)

The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.

In a conversation with CancerNetwork® at the 2025 Kidney Cancer Research Summit, Eric Jonasch, MD, outlined the function of the Kidney Cancer Research Consortium, a program designed to facilitate research in diseases such as renal cell carcinoma. Jonasch highlighted the scope and features of the Kidney Cancer Research Consortium as part of a presentation at the meeting.

According to Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, this program includes 7 institutions that collaborate on various hypothesis-testing clinical trials assessing novel therapeutic strategies in kidney cancer. He stated that researchers across these institutions may be able to lead more mechanistic and scientifically driven investigations while leveraging correlative samples and quality-of-life data as part of their efforts.

Transcript:

My presentation today was about the Kidney Cancer Research Consortium, which is a DOD KCRP [US Department of Defense Kidney Cancer Research Program]–funded program. This is the congressionally designated medical research program, and they then generated a program for renal cell carcinoma research, which then had various projects. One of those projects is to generate a research consortium, which I now lead.

This is a 7-institution consortium, and our goal is to be able to run tissue-rich, data-rich, hypothesis-testing clinical trials with novel agents. We’ve been doing this now for over 4 years. We now have a portfolio of 10 clinical trials that have either completed, are in progress, or [are] about to open. We’ve been very excited about the results so far.

What we’re able to do here is ask more mechanistic and scientifically driven questions. We’re able to collect correlative samples like circulating tumor DNA samples, tissue samples, as well as quality-of-life data on these clinical trials. [We can] also then do trial-by-trial comparisons, so we essentially can acquire more information from a smaller number of patients in a [smaller] amount of time.

Reference

Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at: 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

Recent Videos
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Related Content
At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab

Russ Conroy
November 12th 2025
Article

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

ELI-002 7P Elicits Robust T-Cell Responses in KRAS+ Pancreatic Cancer

Russ Conroy
November 11th 2025
Article

Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma

Tim Cortese
November 7th 2025
Article

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Micheal C. Soulen, MD, spoke about his presentation on the CapTemY90 trial at the 2025 NANETS Multidisciplinary NET Medical Symposium.

Could Radioembolization Be Added to Chemotherapy for Liver-Dominant NETs?

Roman Fabbricatore
November 7th 2025
Article

Micheal C. Soulen, MD, spoke about his presentation on the CapTemY90 trial at the 2025 NANETS Multidisciplinary NET Medical Symposium.